The biocellular therapy industry includes upstream cell storage, midstream cell technology development, and downstream cell therapy.
The downstream of the biological cell therapy industry chain - cell therapy, the implementation of the main body is the top three hospitals; there are two types of downstream industry models: one for the top three hospitals to carry out this business, the other for the top three hospitals and enterprises cooperation, the company provides Technical services and technical support, the hospital provides a clinical platform to implement treatment behavior.
The global Biotherapeutics Cell Line market was valued at 56 million US$ in 2018 and will reach 100 million US$ by the end of 2025, growing at a CAGR of 7.3% during 2019-2025.
This report focuses on Biotherapeutics Cell Line volume and value at global level, regional level and company level. From a global perspective, this report represents overall Biotherapeutics Cell Line market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Biotherapeutics Cell Line in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Biotherapeutics Cell Line manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Becton Dickinson
Beckman Coulter
Boehringer Ingelheim Pharma
CMC Biologics
Catalent
Lonza Group
ProBioGen
Partec
SAFC
Sony Biotechnology
Selexis
Thermo Fisher Scientific
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Single Cell Cloning
Transfection and Selection
Segment by Application
Cancer
Other
The downstream of the biological cell therapy industry chain - cell therapy, the implementation of the main body is the top three hospitals; there are two types of downstream industry models: one for the top three hospitals to carry out this business, the other for the top three hospitals and enterprises cooperation, the company provides Technical services and technical support, the hospital provides a clinical platform to implement treatment behavior.
The global Biotherapeutics Cell Line market was valued at 56 million US$ in 2018 and will reach 100 million US$ by the end of 2025, growing at a CAGR of 7.3% during 2019-2025.
This report focuses on Biotherapeutics Cell Line volume and value at global level, regional level and company level. From a global perspective, this report represents overall Biotherapeutics Cell Line market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Biotherapeutics Cell Line in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Biotherapeutics Cell Line manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Becton Dickinson
Beckman Coulter
Boehringer Ingelheim Pharma
CMC Biologics
Catalent
Lonza Group
ProBioGen
Partec
SAFC
Sony Biotechnology
Selexis
Thermo Fisher Scientific
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Single Cell Cloning
Transfection and Selection
Segment by Application
Cancer
Other
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.